Evercore ISI analyst Cory Kasimov raised the firm’s price target on Cytokinetics (CYTK) to $80 from $60 and keeps an Outperform rating on the shares following what the firm describes as “a stellar showing at the ESC Congress in Madrid.” The company’s MAPLE study is “poised to redefine first-line therapy options,” while Bristol Myers’ (BMY) ODYSSEY data on mavacamten “hints at a promising outlook” for Cytokinetics’ ACACIA trial in the first half of 2026, the analyst tells investors following the medical meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- ‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results
- Cytokinetics Highlights Aficamten Data at ESC Congress
- Cytokinetics price target raised to $71 from $53 at Barclays
- Cytokinetics Reveals Promising MAPLE-HCM Trial Results
- Kraft Heinz announces separation, Elliott builds $4B PepsiCo stake: Morning Buzz